The authors regret that the median PFS data given in the Efficacy section of the Results were inaccurately given as
ESMO Open published a clinical update in Oncology on 10 Mar 2026.
The item focuses on Corrigendum to ‘Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer’.
Review the original article for the full source wording and details.